Dr. Panagiotis Kassavetis, MD

Dr. Kassavetis practices at Medical Faculty Associates, Inc in Washington, District of Columbia.

Dr. Kassavetis' NPI, 1528473782, was assigned on June 26, 2014. Dr. Kassavetis holds Utah license 12099433-1205.

Dr. Kassavetis' primary practice is Medical Faculty Associates, Inc, at 2150 Pennsylvania NW Ave, Washington, DC 20037 in District Of Columbia County. The practice phone is (202) 741-3350.

Dr. Kassavetis' primary practice is Medical Faculty Associates, Inc in Washington, District of Columbia. Dr. Kassavetis is also affiliated with The George Washington University Hospital. The medical group on file is The GW Medical Faculty Associates. Dmand AI also links Dr. Kassavetis to 1 more group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kassavetis practices, 2 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kassavetis' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Kassavetis' licenses on file in 2 states: Utah and Massachusetts.

CMS data shows 467 Medicare services from Dr. Kassavetis across 7 procedure codes in 2024, for 207 Medicare patients. Medicare paid $34,354 for them. Every service was in an office.

CMS counts 207 Medicare patients who saw Dr. Kassavetis in 2024. The largest group is 65 to 74, with 91 patients. 64% of them have high blood pressure, and 64% have high cholesterol. 15% are also on Medicaid. Their average risk score is 1.45, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kassavetis' median patient age at 72, with 52% women.

In 2024, Dr. Kassavetis wrote 614 Medicare Part D claims for 180 patients. 91% of them were for generic drugs. CMS names the drug for 521 of them, across 11 drugs with 11 or more claims each, at $49,521 in total drug cost. In 2023, CMS named 619 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 90 out of 100 for Dr. Kassavetis for performance year 2024, reported as part of a group. Dr. Kassavetis accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kassavetis as offering telehealth. CMS counts 20 procedures of skin biopsy by Dr. Kassavetis, more than 63% of the clinicians it reports for that procedure.

Dmand AI links 58 papers to Dr. Kassavetis, published from 2011 to 2024. 2014 was the busiest year, with 9. The most frequent topics are Transcranial Magnetic Stimulation, Electromyography and Neural Inhibition. Dr. Kassavetis has published most often in Mov Disord. Dr. Kassavetis' most frequent co-authors are Paolo M. Moretti, MD, Katharine E. Alter, MD and Pablo Ariel Celnik, MD.

CMS Open Payments shows 22 general payments to Dr. Kassavetis from 2 drug and device companies from 2024 to 2025. Travel and lodging make up the largest share, 51% of the total. Merz Pharmaceuticals, LLC paid the most, $8,049.